Dupixent® (dupilumab) is now approved in India for the treatment of adults with moderate-to-severe atopic dermatitis

Dupixent treatment for atopic dermatitis"

Sanofi Healthcare India has broken new ground with the approval of its biologic medicine, Dupixent® (dupilumab). It offers a ray of hope to adults with moderate-to-severe atopic dermatitis who have not been successful with topical prescription therapies or for whom these therapies aren’t recommended. In stark contrast to traditional treatments that suppress the immune system broadly, Dupixent® targets the underlying type 2 inflammation, thereby revolutionizing treatment approaches globally.

The atopic dermatitis treatment spectrum has been fraught with limited options for sufferers. This chronic skin disease causes severe itching, dryness, redness, and other uncomfortable symptoms. With Dupixent®’s approval in India, patients can now look forward to an alternative treatment that has shown significant improvements in disease signs, symptoms, and overall quality of life.

Developed through a global collaboration between Sanofi and Regeneron, Dupixent® has proven successful in over 60 countries. Having treated more than 600,000 patients worldwide, it now prepares to serve the Indian demographic afflicted by moderate-to-severe atopic dermatitis.


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *